8-K: Current report filing
Published on January 4, 2023
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Exact name of registrant as specified in its charter) |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
| (Registrant's telephone number, including area code) |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[ ]
Item 8.01 Other Events.
On January 4, 2023, Know Labs, Inc. (the “Company”) published a press release disclosing details on a new foundational patent granted by the United States Patent and Trademark Office. U.S. Patent No. 11,529,077, titled High Performance Glucose Sensor. This patent equates the Company’s Bio-RFIDTM diagnostic technology to the current reference standard for glucose monitoring, widely used by diabetes researchers, hospital labs and glucometer manufacturers, and establishes a specific, superior benchmark range of clinical accuracy, known as MARD, for the Bio-RFID diagnostic platform.
The new patent extends the Know Labs IP portfolio to nearly 90 patents issued and pending, reinforcing the Company’s position as a top worldwide IP holder in non-invasive blood glucose monitoring.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release dated January 4, 2023 - Filed herewith. |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: January 4, 2023 | KNOW LABS, INC. |
| /s/ Ronald P. Erickson | |
| Name: Ronald P. Erickson | |
| Title: Chairman of the Board |
- 3 -